institutionsInstitution
Antwerp University Hospital (UZA)
aka UZA, Universitair Ziekenhuis Antwerpen
Belgium's Antwerp university hospital, where Jan Vermorken led EXTREME, the trial that made cetuximab plus chemotherapy the first-line standard for recurrent head and neck cancer for a decade.
Overview
Antwerp University Hospital (UZA) is the academic hospital of the University of Antwerp, at Edegem south of the city. Its Department of Medical Oncology, under Jan Vermorken, coordinated the EXTREME trial, reported in the New England Journal of Medicine in 2008, in which adding cetuximab to platinum and fluorouracil lengthened survival in recurrent or metastatic head and neck squamous-cell carcinoma. The department has long been active in EORTC gynaecological and head and neck trials.
Location
Edegem, BE
Type
hospital · Universiteit Antwerpen
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#644 · 2 points (0 Newsweek + 0 NCI + 2 from 1 linked objects) · ranking
- Head and neck cancer
- Gynaecological cancer
- EORTC trials
Similar pages
not linked directly; found by shared links- TrialEXTREME
Shares Jan B. Vermorken, Head and neck squamous cell carcinoma.